Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addition to disease-related immunosuppression and myelosuppression. We conducted an international, open-label, randomized phase 3 trial to compare two oral agents, ibrutinib and chlorambucil, in previously untreated older patients with CLL or small lymphocytic lymphoma.
hronic lymphocytic leukemia (CLL) is the most common leukemia among adults in Western countries; it affects primarily older persons, with a median age at diagnosis of 72 years. 1, 2 Chlorambucil has been a standard first-line therapy in CLL, especially for older patients or those with coexisting conditions. 1, 3 Until recently, no treatment was clearly superior to chlorambucil in this population. [3] [4] [5] [6] [7] Fludarabine or bendamustine has been associated with higher response rates and longer progression-free survival than those with chlorambucil, but both have also been associated with higher rates of toxic effects, and neither has provided overall survival benefit. 3, 5, 6, 8 In previously untreated patients who were younger than 75 years of age, bendamustine was associated with longer progression-free survival as compared with chlorambucil (median, 21.6 months vs. 8.3 months). 5 Only recently have data from randomized studies shown improved outcomes with the addition of anti-CD20 monoclonal antibodies to chlorambucil. 9, 10 In the three-group randomized CLL11 study conducted by the German CLL Study Group, which involved previously untreated patients with coexisting conditions, the median progression-free survival was 29.9 months with the combination of obinutuzumab and chlorambucil, 16.3 months with the combination of rituximab and chlorambucil, and 11.1 months with chlorambucil alone; overall survival was longer with the combination regimens than with chlorambucil. 11 In another phase 3 study, which involved previously untreated patients who were not considered to be candidates for fludarabinecontaining therapy, the median progression-free survival was 13.1 months with chlorambucil versus 22.4 months with the combination of chlorambucil and ofatumumab. 10 Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab is standard in younger patients with CLL, 12 but because of treatment-related toxic effects, this regimen is not suitable for older patients or those with coexisting conditions. 13 Patients who are 65 years of age or older do not have the same efficacy benefit, and they have more toxic effects than do younger patients treated with this combination chemoimmunotherapy. [13] [14] [15] Moreover, although the median progression-free survival with first-line fludarabine, cyclophosphamide, and rituximab is approximately 52 months, patients with high-risk genetic abnormalities (chromosome 17p13.1 or 11q22.3 deletion) or unmutated IGHV have inferior outcomes, with approximately 35 to 50% of the patients having progressive disease within 3 years. 12 Ibrutinib is a first-in-class oral covalent inhibitor of Bruton's tyrosine kinase (BTK) that has been approved for the treatment of patients with CLL who have received at least one prior therapy and as primary therapy for patients with CLL who have chromosome 17p13.1 deletion. 16, 17 BTK is essential for signaling by means of the B-cell receptor and chemokine receptors, which CLL cells use for survival, proliferation, and tissue homing. [18] [19] [20] [21] [22] In pharmacodynamic studies of ibrutinib in vivo in patients with CLL, ibrutinib inhibited leukemia-cell proliferation and accelerated CLL cell death. [23] [24] [25] In the phase 3 Study of Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (RESONATE) involving patients with previously treated CLL, single-agent ibrutinib showed superior efficacy to ofatumumab, with a risk of progression that was 78% lower and a risk of death that was 57% lower. 26 In early-phase data from 31 previously untreated patients with CLL who were 65 years of age or older, the overall response rate with ibrutinib was 84% (with a complete response in 23% of the patients); the estimated rate of progression-free survival at 30 months was 96%, and the overall survival rate was 97%, with 81% of the patients continuing to take daily ibrutinib after 3 years of follow-up. 27 These findings suggest a role for single-agent ibrutinib as initial treatment in patients with CLL. We conducted a multicenter, open-label, randomized phase 3 trial (RESONATE-2; study number, PCYC-1115-CA) to evaluate the efficacy and safety of single-agent ibrutinib as compared with chlorambucil in patients 65 years of age or older with previously untreated CLL.
Me thods

Patients
Eligible patients were 65 years of age or older and had previously untreated CLL or small lymphocytic lymphoma requiring therapy. 28 Other eligibility criteria included an Eastern Cooperative Oncology Group (ECOG) performance-status score of 2 or less (on a scale from 0 to 5, with 0 indicating no symptoms and higher numbers indicating increasing disability), an absolute neutrophil count of 1000 cells or more per cubic millimeter, a platelet count of 50,000 or more per cubic millimeter, and adequate liver and kidney function. Patients were ineligible if they had chromosome 17p13.1 deletion. All the patients provided written informed consent.
Study Oversight and Conduct
The study was approved by the institutional review board or independent ethics committee at each institution and was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines. The study was sponsored and designed by Pharmacyclics. All the investigators and their research teams collected the data. The sponsor confirmed the accuracy of the data and compiled the data for analysis. All the authors had full access to the data and were involved in the interpretation of the data. The first draft of the manuscript was collaboratively written by the first and last authors and two authors who are employees of the sponsor. Editorial support was provided by a professional medical writer, with funding from the sponsor. All the authors contributed to the revisions and final approval of the manuscript and made the decision to submit the manuscript for publication. All the authors vouch for the accuracy and completeness of the reported data and analyses and confirm adherence of the trial to the protocol (available with the full text of this article at NEJM.org). An independent review committee whose members were unaware of the treatment assignments and lymphocyte counts evaluated response and progression.
Randomization and Treatment
Patients were enrolled in the United States, countries in Europe, and other countries (see the Supplementary Appendix, available at NEJM.org). Patients were randomly assigned, in a 1:1 ratio, to receive either oral ibrutinib (at a dose of 420 mg once daily) until disease progression or development of an unacceptable level of toxic effects or up to 12 cycles of chlorambucil (at a dose of 0.5 mg per kilogram of body weight on days 1 and 15 of each 28-day cycle, which was increased to a maximum of 0.8 mg per kilogram, if there was not an unacceptable level of toxic effects) until disease progression, determination of a lack of efficacy (defined as a lack of complete or partial response, as determined by the investigator), or development of an unacceptable level of toxic effects.
Patients with disease progression that was confirmed by the independent review committee were enrolled in a separate extension study (PCYC-1116-CA) for follow-up and second-line treatment according to the investigator's choice. Treatment in the PCYC-1116-CA study could include ibrutinib for chlorambucil-treated patients who had disease that progressed according to the independent review committee and who had an indication for treatment according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria 28 ( Table S1 in the Supplementary Appendix) as determined by the investigator.
Study End Points
The primary end point was progression-free survival, as assessed by the independent review committee according to the iwCLL criteria, 28 with modification for treatment-related lymphocytosis such that isolated treatment-related lymphocytosis (in the absence of other clinical, computed tomographic, or laboratory evidence of disease progression) was not considered to indicate progressive disease. 29 Key secondary end points included overall survival, overall response (details in Table S2 in the Supplementary Appendix), the rate of sustained improvement in hematologic variables, and safety. Sustained hematologic improvement was defined as an increase in hematologic variables that was sustained continuously for at least 56 days without transfusion or growth factors, as measured by the following: an increase in the platelet count or absolute neutrophil count from baseline of at least 50%, or for hemoglobin, an increase from baseline of ≥2 g per deciliter; or for patients with baseline cytopenia, an increase to a hemoglobin level of more than 11 g per deciliter, a platelet count of more than 100,000 per cubic millimeter, or an absolute neutrophil count of more than 1500 per cubic millimeter.
Safety assessments included evaluation of adverse events and measurement of laboratory variables. The severity of nonhematologic adverse events was graded according to the Common n engl j med 373;25 nejm.org december 17, 2015
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T h e ne w e ngl a nd jou r na l o f m e dicine Terminology Criteria for Adverse Events, version 4.03. 30 Hematologic adverse events were graded according to the iwCLL criteria. 28 Patients were monitored every 2 weeks during cycles 1 and 2, every 4 weeks during cycles 3 through 12, and then every 8 weeks starting at cycle 13. The assessment of response was conducted every 4 cycles until disease progression or until study closure.
Statistical Analysis
The study was powered on the basis of the primary end point, progression-free survival. We calculated that the occurrence of 81 events of death or disease progression would provide the study with approximately 85% power to detect a hazard ratio for progression or death of 0.50 with ibrutinib as compared with chlorambucil, with the use of a one-sided log-rank test at an alpha level of 0.025. No interim analysis was planned. The type I error was controlled with the use of a hierarchical closed-testing procedure for the primary end point and ordered secondary end points including, in order, overall response rate, overall survival, and sustained hematologic improvement.
The primary analysis was a two-sided log-rank test stratified according to two randomization factors: ECOG performance-status score (0 or 1 vs. 2) and disease stage (Rai stage ≤II vs. III or IV). The overall response rate was analyzed by means of the Cochran-Mantel-Haenszel chi-square test, stratified according to the two randomization factors. Overall survival was analyzed with the use of an unstratified log-rank test, owing to small event numbers. The rate of sustained hematologic improvement was compared by a chi-square test for treatment effect.
R esult s
Patients
Beginning in March 2013, a total of 269 patients underwent randomization (Fig. S1 in the Supplementary Appendix). The characteristics of the patients at baseline were well balanced between the two groups ( Table 1 ). The median age of the patients was 73 years, with 70% of the patients being 70 years of age or older; 45% of the patients had advanced-stage disease (Rai stage III or IV), and 20% had chromosome 11q22.3 deletion.
The median follow-up was 18.4 months, with 87% of the patients who had been randomly assigned to ibrutinib still receiving treatment at the time of analysis. In the chlorambucil group, 40% of the patients completed the maximum of 12 cycles of treatment (mean dose per administration, 0.6 mg per kilogram; range, 0.3 to 0.8).
Efficacy
Progression-free Survival
Ibrutinib resulted in significantly longer progression-free survival than that with chlorambucil (median, not reached vs. 18.9 months) as assessed by the independent review committee, with a relative risk of progression or death that was 84% lower than that with chlorambucil (hazard ratio, 0.16; 95% confidence interval [CI], 0.09 to 0.28; P<0.001) (Fig. 1A) . The rate of progression-free survival at 18 months was 90% in the ibrutinib group versus 52% in the chlorambucil group.
The results of the analysis of progression-free survival were consistent in the higher-risk subgroups, including patients with Rai stage III or IV disease, worse ECOG performance-status score, presence of chromosome 11q22.3 deletion, and unmutated IGHV status (Fig. 1C) . The rate of progression-free survival at 18 months with ibrutinib was approximately 89% both in the subgroup with unmutated IGHV and in the subgroup with mutated IGHV; the corresponding rates of progression-free survival with chlorambucil were 47% and 51%. Investigator-assessed progression-free survival, a key sensitivity analysis, also showed significant prolongation of progression-free survival with ibrutinib (median, not reached vs. 15.0 months), with a relative risk of progression or death that was 91% lower than that with chlorambucil (hazard ratio, 0.09; 95% CI, 0.04 to 0.17; P<0.001) (Fig. 1B) . The only case of Richter's transformation (CLL that has evolved into an aggressive, rapidly growing large-cell lymphoma) occurred in the chlorambucil group.
Overall Survival
Ibrutinib significantly prolonged overall survival (median, not reached in either group). The overall survival rate at 24 months was 98% with ibrutinib versus 85% with chlorambucil, with a relative risk of death with ibrutinib that was 84% lower than that with chlorambucil (hazard ratio, 0.16; 95% CI, 0.05 to 0.56; P = 0.001) ( Fig. 2A) .
Over the median follow-up of 18.4 months, 3 patients in the ibrutinib group died, as compared with 17 in the chlorambucil group. The 3 patients in the ibrutinib group who died included 1 who died from a klebsiella infection and 2 who died from unknown causes (Table S3 in the Supplementary Appendix). Among the 17 patients in the chlorambucil group who died, the most common causes were progressive disease and infection. None of the patients in the ibrutinib group who had disease that progressed died during follow-up.
Response
The response rate as assessed by the independent review committee was significantly higher * There were no significant between-group differences at baseline. † Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with 0 indicating no symptoms and higher numbers indicating increasing disability. ‡ Measurement was based on the longest diameter of the largest lymph node at screening, according to assessment by an independent review committee. § Scores on the Cumulative Illness Rating Scale range from 0 to 52, with higher scores indicating worse health status. T in the ibrutinib group than in the chlorambucil group (86% vs. 35%) (Fig. 2B) ; 4% of the patients in the ibrutinib group had a partial response with lymphocytosis. Details regarding the frequency and duration of lymphocytosis with ibrutinib are provided in Table S4 in the Supplementary Appendix. Complete responses (including those in patients with incomplete bloodcount recovery) occurred in 4% of the patients in the ibrutinib group and in 2% of those in the chlorambucil group (Fig. 2B) .
Hematologic Variables
The rates of sustained improvement in hematologic variables were significantly higher with ibrutinib than with chlorambucil (Table S5 in Supplementary Appendix). Among patients with anemia at baseline, a significantly higher proportion of patients in the ibrutinib group than in the chlorambucil group had sustained improvement in the hemoglobin level (84% vs. 45%, P<0.001) ( Table S6 in the Supplementary Appendix). Similarly, among patients who had thrombocytopenia at baseline, a significantly higher proportion of patients in the ibrutinib group than in the chlorambucil group had sustained improvement in the platelet count (77% vs. 43%, P = 0.005). Changes in hematologic variables over time are shown in Figure 3 .
Safety
The most common adverse events, defined as those that occurred in 15% or more of the patients in either treatment group, are shown in Table 2 and in Table S7 in the Supplementary Appendix. The median period of exposure to the study treatment was 17.4 months (range, 0.7 to 24.7) in the ibrutinib group versus 7.1 months (range, 0.5 to 11.7) in the chlorambucil group, hence the corresponding collection period for adverse-event data was longer in the ibrutinib group. In the ibrutinib group, diarrhea was the most frequent adverse event (in 42% of the patients, including grade 3 diarrhea in 4%) ( Table  S7 in the Supplementary Appendix). Other adverse events that occurred in 20% or more of the patients in the ibrutinib group were fatigue, nausea, and cough. In the chlorambucil group, nausea, fatigue, neutropenia, anemia, and vomiting were observed in 20% or more of the patients; all these events occurred at a higher frequency in the chlorambucil group than in the ibrutinib group (Table S7 in the Supplementary Appendix). Discontinuation of treatment owing to adverse events occurred less frequently in the ibrutinib group than in the chlorambucil group (in 9% vs. 23% of the patients). Adverse events of grade 3 or higher and serious adverse events are listed in Table 2 . Hypertension was observed in 14% of the patients in the ibrutinib group, with grade 3 hypertension occurring in 4% and no events of grade 4 or 5. All six patients with grade 3 hypertension were treated with antihypertensive medication and did not require a dose reduction or discontinuation of ibrutinib. Four of these patients had a history of hypertension; blood-pressure values over time in these patients are shown in Figure S2 in the Supplementary Appendix.
Atrial fibrillation occurred in eight patients (6%) in the ibrutinib group, which was of grade 2 in six patients and grade 3 in two. Atrial fibrillation was managed with discontinuation of the study drug in two patients (1%) and without modification of the ibrutinib dose in the remaining six patients. Seven of these eight patients had a history of hypertension, coronary artery disease, or myocardial ischemia. One patient in the chlorambucil group had atrial fibrillation.
During a median of 17.4 months of exposure to ibrutinib, major hemorrhage (defined as any min E at the time of the event. Major hemorrhage in the central nervous system included one grade 4 intraparenchymal hemorrhage related to transformation of an ischemic stroke in a patient with diabetes and hypertension and one grade 3 post-traumatic subdural hematoma. Major hemorrhage occurred in 2% of the patients in the chlorambucil group over the 7.1-month period of exposure.
Discussion
In this randomized study involving older patients with previously untreated CLL or small lymphocytic lymphoma, ibrutinib was superior to chlorambucil with respect to progression-free and overall survival, response rate, and improvement in hematologic variables. The relative risk of progression was 84% lower and the relative risk of death was also 84% lower with ibrutinib than with chlorambucil. Ibrutinib toxicity was modest in the majority of patients, with 87% of the patients continuing to take the single-agent therapy at a median follow-up of 18.4 months. All current standards for first-line CLL therapy are based on cytotoxic chemotherapy, including alkylating agents, purine analogues, or combinations thereof, except for patients with chromosome 17p13.1 deletion, for whom ibrutinib is a primary consideration for first-line therapy according to consensus guidelines. 16, 17, 31, 32 In addition to their myelosuppressive effects, these cytotoxic chemotherapy approaches may be associated with expansion of subclones with high-risk genetic abnormalities (e.g., TP53 or NOTCH1 mutation) [33] [34] [35] and an increased risk of secondary cancers, including treatment-related myelodysplasia and acute myeloid leukemia. 36, 37 When this study was initiated, single-agent chlorambucil was considered to be a standard first-line treatment in older patients with CLL. 1, 31, 38, 39 Phase 3 studies have only recently shown improvement in outcomes when chlorambucil is coadministered with anti-CD20 monoclonal antibodies. 9, 10 Depending on the anti-CD20 agent used in these combinations, the median progression-free survival has been reported as 16.3 months (with rituximab and chlorambucil), 11 22.4 months (with ofatumumab and chlorambucil), 10 and 29.9 months (with obinutuzumab and chlorambucil). 11 The addition of an anti-CD20 agent that requires a slow infusion has been associated with infusion reactions of grade 3 or higher (in 4 to 20% of patients) and with higher rates of neutropenia of grade 3 or higher (in 27 to 35%) than have been observed with chlorambucil alone. 9, 10 Similar to results observed in patients with relapsed disease, the finding of a positive effect of ibrutinib on progression-free survival in the current study was seen in high-risk subgroups, including patients with Rai stage III or IV disease, those with chromosome 11q22.3 deletion, and those with unmutated IGHV. At 18 months, the rate of progression-free survival with ibrutinib as assessed by the independent review committee was 90%, and the rate as assessed by the investigator was 94%; the median progressionfree survival with ibrutinib could not be estimated owing to the small number of progression events. The median progression-free survival of 18.9 months with chlorambucil that was observed in this study appears to be generally longer than that reported in previous trials with chlorambucil in previously untreated patients, in which the median progression-free survival ranged from 8.3 to 20.0 months. [3] [4] [5] 8, 10, 11 The relatively strong performance of chlorambucil in the current study may have been influenced, in part, by a generally longer exposure to Shown are overall survival with ibrutinib versus chlorambucil (Panel A) and the best response to treatment as assessed by the independent review committee (Panel B). The tick marks indicate patients with censored data. Categories for response assessments included complete response (CR) or complete response with incomplete blood-count recovery (CRi), nodular partial response (nPR; according to the International Workshop on Chronic Lymphocytic Leukemia criteria for response, 28 nPR was defined as a complete response with lymphoid nodules in the bone marrow), partial response (PR), partial response with lymphocytosis (PR-L), stable disease, and progressive disease. In the ibrutinib group, five patients (4%) had a complete response and one (1%) had a complete response with incomplete bloodcount recovery. In the chlorambucil group, two patients (2%) had a complete response. Data were unknown, missing, or could not be evaluated for six patients in the ibrutinib group and for eight in the chlorambucil group. The rate ratios and P values are based on the Cochran-Mantel-Haenszel chi-square test, stratified according to ECOG performance-status score (0 or chlorambucil than was used in earlier trials involving previously untreated patients with CLL or by the exclusion of patients with chromosome 17p13.1 deletion (typically 5 to 10% of previously untreated patients with CLL).
Ibrutinib substantially improved overall survival, with an overall survival rate of 98% at 24 months, a finding that is consistent with the 97% rate reported in a phase 2 study of ibrutinib with 3 years of follow-up. 27 In these two studies, deaths (3 deaths among 136 patients and 1 death among 31 patients, respectively) were limited to the early part of follow-up with a relative plateau in the survival curve thereafter. The magnitude of the difference in overall survival with ibrutinib as compared with chlorambucil (hazard ratio for death, 0.16) was greater than that observed in studies assessing the addition of anti-CD20 agents to chlorambucil (hazard ratio, 0.47 in one study 11 and 0.91 in another study 10 ). Given the availability of crossover for patients who had disease that progressed during chlorambucil treatment, the prolongation of overall survival, which was a major benefit in this study, suggests that patients have benefits with first-line ibrutinib treatment possibly owing to reduced CLL-related or treatment-related mortality before the initiation of second-line therapy. These findings suggest that better results with ibrutinib might be obtained when it is used as first-line treatment rather than for later relapses or in patients with refractory disease.
The response rate was significantly higher with ibrutinib than with chlorambucil (86% vs. 35%). On the basis of results from an earlyphase study, 27 the rate of complete response is likely to increase with continued ibrutinib therapy. Furthermore, ibrutinib-treated patients had a restoration of bone marrow function, with a significantly higher rate of sustained improvement in hematologic variables. This finding has particular clinical relevance because bone marrow failure is a common cause of complications in patients with CLL, with anemia and thrombocytopenia being frequent indications for initiating treatment in this population. 28 The safety of ibrutinib in this older population of patients with CLL who often had clinically significant coexisting conditions (Table 1) was consistent with that in previous reports. Exposure to treatment and adverse-event followup was nearly 2.5 times as long with ibrutinib as with chlorambucil. Similar to findings in previous reports about ibrutinib, major hemorrhage was observed in 4% of the patients, with no fatal events, and atrial fibrillation occurred in 6%, with the majority of the events (in six of eight patients) being grade 2 events that were observed over the period of 1.5 years while the patients were taking ibrutinib. Hypertension was reported more frequently with ibrutinib than with chlorambucil, with no events leading * The events listed are adverse events of any grade that occurred in at least 15% of patients in either treatment group and for which the frequency differed between treatment groups by at least 5%. † The events listed are adverse events of grade 3 or higher or serious adverse events that occurred in at least 2% of the patients in either treatment group. One death due to toxic hepatitis in the chlorambucil group was considered by the investigator to be possibly related to the study treatment; no other deaths were considered by the investigator to be related to the study treatment. to dose modification or having a severity of grade 4 or 5. The rates of fatigue, nausea, vomiting, and myelosuppression were higher with chlorambucil than with ibrutinib. Early discontinuation of treatment due to adverse events was more than twice as frequent with chlorambucil as with ibrutinib.
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